img

Global Neuroprotective Agents Market Insights, Forecast to 2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Neuroprotective Agents Market Insights, Forecast to 2034

Neuroprotective agents are medications that can alter the course of metabolic events after the onset of ischemia and therefore have the potential to reduce stroke damage.
The global Neuroprotective Agents market is projected to grow from US$ million in 2024 to US$ million by 2034, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Neuroprotective Agents is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The China market for Neuroprotective Agents is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The Europe market for Neuroprotective Agents is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The global key manufacturers of Neuroprotective Agents include Genervon Biopharmaceuticals, NeuroVive Pharmaceutical, Ceregene, Neuren Pharmaceuticals and Allon Therapeutics, etc. In 2022, the global top five players had a share approximately % in terms of revenue.

Report Includes


This report presents an overview of global market for Neuroprotective Agents, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2018 - 2022, estimates for 2024, and projections of CAGR through 2034.
This report researches the key producers of Neuroprotective Agents, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Neuroprotective Agents, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Neuroprotective Agents sales, revenue, market share and industry ranking of main manufacturers, data from 2018 to 2024. Identification of the major stakeholders in the global Neuroprotective Agents market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2018 to 2034. Evaluation and forecast the market size for Neuroprotective Agents sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Genervon Biopharmaceuticals, NeuroVive Pharmaceutical, Ceregene, Neuren Pharmaceuticals and Allon Therapeutics, etc.



By Company


Genervon Biopharmaceuticals
NeuroVive Pharmaceutical
Ceregene
Neuren Pharmaceuticals
Allon Therapeutics
Segment by Type
Cerebrovascular Diseases
Neurodegenerative Disorders
Ophthalmic Diseases
Traumatic CNS Injuries

Segment by Application


Hospitals
Clinics
Others

Segment by Region


US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Neuroprotective Agents in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3Detailed analysis of Neuroprotective Agents manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6US & Canada (US & Canada) by type, by application and by country, sales and revenue for each segment.
Chapter 7Europe by type, by application and by country, sales and revenue for each segment.
Chapter 8China by type, by application sales and revenue for each segment.
Chapter 9Asia (excluding China) by type, by application and by region, sales and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by type, by application and by country, sales and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neuroprotective Agents sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Study Coverage
1.1 Neuroprotective Agents Product Introduction
1.2 Market by Type
1.2.1 Global Neuroprotective Agents Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 Cerebrovascular Diseases
1.2.3 Neurodegenerative Disorders
1.2.4 Ophthalmic Diseases
1.2.5 Traumatic CNS Injuries
1.3 Market by Application
1.3.1 Global Neuroprotective Agents Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Neuroprotective Agents Sales Estimates and Forecasts 2018-2034
2.2 Global Neuroprotective Agents Revenue by Region
2.2.1 Global Neuroprotective Agents Revenue by Region: 2018 VS 2022 VS 2034
2.2.2 Global Neuroprotective Agents Revenue by Region (2018-2024)
2.2.3 Global Neuroprotective Agents Revenue by Region (2024-2034)
2.2.4 Global Neuroprotective Agents Revenue Market Share by Region (2018-2034)
2.3 Global Neuroprotective Agents Sales Estimates and Forecasts 2018-2034
2.4 Global Neuroprotective Agents Sales by Region
2.4.1 Global Neuroprotective Agents Sales by Region: 2018 VS 2022 VS 2034
2.4.2 Global Neuroprotective Agents Sales by Region (2018-2024)
2.4.3 Global Neuroprotective Agents Sales by Region (2024-2034)
2.4.4 Global Neuroprotective Agents Sales Market Share by Region (2018-2034)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Neuroprotective Agents Sales by Manufacturers
3.1.1 Global Neuroprotective Agents Sales by Manufacturers (2018-2024)
3.1.2 Global Neuroprotective Agents Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Neuroprotective Agents in 2022
3.2 Global Neuroprotective Agents Revenue by Manufacturers
3.2.1 Global Neuroprotective Agents Revenue by Manufacturers (2018-2024)
3.2.2 Global Neuroprotective Agents Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Neuroprotective Agents Revenue in 2022
3.3 Global Key Players of Neuroprotective Agents, Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global Neuroprotective Agents Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Neuroprotective Agents Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Neuroprotective Agents, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Neuroprotective Agents, Product Offered and Application
3.8 Global Key Manufacturers of Neuroprotective Agents, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Neuroprotective Agents Sales by Type
4.1.1 Global Neuroprotective Agents Historical Sales by Type (2018-2024)
4.1.2 Global Neuroprotective Agents Forecasted Sales by Type (2024-2034)
4.1.3 Global Neuroprotective Agents Sales Market Share by Type (2018-2034)
4.2 Global Neuroprotective Agents Revenue by Type
4.2.1 Global Neuroprotective Agents Historical Revenue by Type (2018-2024)
4.2.2 Global Neuroprotective Agents Forecasted Revenue by Type (2024-2034)
4.2.3 Global Neuroprotective Agents Revenue Market Share by Type (2018-2034)
4.3 Global Neuroprotective Agents Price by Type
4.3.1 Global Neuroprotective Agents Price by Type (2018-2024)
4.3.2 Global Neuroprotective Agents Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Neuroprotective Agents Sales by Application
5.1.1 Global Neuroprotective Agents Historical Sales by Application (2018-2024)
5.1.2 Global Neuroprotective Agents Forecasted Sales by Application (2024-2034)
5.1.3 Global Neuroprotective Agents Sales Market Share by Application (2018-2034)
5.2 Global Neuroprotective Agents Revenue by Application
5.2.1 Global Neuroprotective Agents Historical Revenue by Application (2018-2024)
5.2.2 Global Neuroprotective Agents Forecasted Revenue by Application (2024-2034)
5.2.3 Global Neuroprotective Agents Revenue Market Share by Application (2018-2034)
5.3 Global Neuroprotective Agents Price by Application
5.3.1 Global Neuroprotective Agents Price by Application (2018-2024)
5.3.2 Global Neuroprotective Agents Price Forecast by Application (2024-2034)
6 US & Canada
6.1 US & Canada Neuroprotective Agents Market Size by Type
6.1.1 US & Canada Neuroprotective Agents Sales by Type (2018-2034)
6.1.2 US & Canada Neuroprotective Agents Revenue by Type (2018-2034)
6.2 US & Canada Neuroprotective Agents Market Size by Application
6.2.1 US & Canada Neuroprotective Agents Sales by Application (2018-2034)
6.2.2 US & Canada Neuroprotective Agents Revenue by Application (2018-2034)
6.3 US & Canada Neuroprotective Agents Market Size by Country
6.3.1 US & Canada Neuroprotective Agents Revenue by Country: 2018 VS 2022 VS 2034
6.3.2 US & Canada Neuroprotective Agents Sales by Country (2018-2034)
6.3.3 US & Canada Neuroprotective Agents Revenue by Country (2018-2034)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Neuroprotective Agents Market Size by Type
7.1.1 Europe Neuroprotective Agents Sales by Type (2018-2034)
7.1.2 Europe Neuroprotective Agents Revenue by Type (2018-2034)
7.2 Europe Neuroprotective Agents Market Size by Application
7.2.1 Europe Neuroprotective Agents Sales by Application (2018-2034)
7.2.2 Europe Neuroprotective Agents Revenue by Application (2018-2034)
7.3 Europe Neuroprotective Agents Market Size by Country
7.3.1 Europe Neuroprotective Agents Revenue by Country: 2018 VS 2022 VS 2034
7.3.2 Europe Neuroprotective Agents Sales by Country (2018-2034)
7.3.3 Europe Neuroprotective Agents Revenue by Country (2018-2034)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Neuroprotective Agents Market Size
8.1.1 China Neuroprotective Agents Sales (2018-2034)
8.1.2 China Neuroprotective Agents Revenue (2018-2034)
8.2 China Neuroprotective Agents Market Size by Application
8.2.1 China Neuroprotective Agents Sales by Application (2018-2034)
8.2.2 China Neuroprotective Agents Revenue by Application (2018-2034)
9 Asia (excluding China)
9.1 Asia Neuroprotective Agents Market Size by Type
9.1.1 Asia Neuroprotective Agents Sales by Type (2018-2034)
9.1.2 Asia Neuroprotective Agents Revenue by Type (2018-2034)
9.2 Asia Neuroprotective Agents Market Size by Application
9.2.1 Asia Neuroprotective Agents Sales by Application (2018-2034)
9.2.2 Asia Neuroprotective Agents Revenue by Application (2018-2034)
9.3 Asia Neuroprotective Agents Sales by Region
9.3.1 Asia Neuroprotective Agents Revenue by Region: 2018 VS 2022 VS 2034
9.3.2 Asia Neuroprotective Agents Revenue by Region (2018-2034)
9.3.3 Asia Neuroprotective Agents Sales by Region (2018-2034)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Neuroprotective Agents Market Size by Type
10.1.1 Middle East, Africa and Latin America Neuroprotective Agents Sales by Type (2018-2034)
10.1.2 Middle East, Africa and Latin America Neuroprotective Agents Revenue by Type (2018-2034)
10.2 Middle East, Africa and Latin America Neuroprotective Agents Market Size by Application
10.2.1 Middle East, Africa and Latin America Neuroprotective Agents Sales by Application (2018-2034)
10.2.2 Middle East, Africa and Latin America Neuroprotective Agents Revenue by Application (2018-2034)
10.3 Middle East, Africa and Latin America Neuroprotective Agents Sales by Country
10.3.1 Middle East, Africa and Latin America Neuroprotective Agents Revenue by Country: 2018 VS 2022 VS 2034
10.3.2 Middle East, Africa and Latin America Neuroprotective Agents Revenue by Country (2018-2034)
10.3.3 Middle East, Africa and Latin America Neuroprotective Agents Sales by Country (2018-2034)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Genervon Biopharmaceuticals
11.1.1 Genervon Biopharmaceuticals Company Information
11.1.2 Genervon Biopharmaceuticals Overview
11.1.3 Genervon Biopharmaceuticals Neuroprotective Agents Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 Genervon Biopharmaceuticals Neuroprotective Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Genervon Biopharmaceuticals Recent Developments
11.2 NeuroVive Pharmaceutical
11.2.1 NeuroVive Pharmaceutical Company Information
11.2.2 NeuroVive Pharmaceutical Overview
11.2.3 NeuroVive Pharmaceutical Neuroprotective Agents Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 NeuroVive Pharmaceutical Neuroprotective Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 NeuroVive Pharmaceutical Recent Developments
11.3 Ceregene
11.3.1 Ceregene Company Information
11.3.2 Ceregene Overview
11.3.3 Ceregene Neuroprotective Agents Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 Ceregene Neuroprotective Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Ceregene Recent Developments
11.4 Neuren Pharmaceuticals
11.4.1 Neuren Pharmaceuticals Company Information
11.4.2 Neuren Pharmaceuticals Overview
11.4.3 Neuren Pharmaceuticals Neuroprotective Agents Sales, Price, Revenue and Gross Margin (2018-2024)
11.4.4 Neuren Pharmaceuticals Neuroprotective Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Neuren Pharmaceuticals Recent Developments
11.5 Allon Therapeutics
11.5.1 Allon Therapeutics Company Information
11.5.2 Allon Therapeutics Overview
11.5.3 Allon Therapeutics Neuroprotective Agents Sales, Price, Revenue and Gross Margin (2018-2024)
11.5.4 Allon Therapeutics Neuroprotective Agents Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Allon Therapeutics Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Neuroprotective Agents Industry Chain Analysis
12.2 Neuroprotective Agents Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Neuroprotective Agents Production Mode & Process
12.4 Neuroprotective Agents Sales and Marketing
12.4.1 Neuroprotective Agents Sales Channels
12.4.2 Neuroprotective Agents Distributors
12.5 Neuroprotective Agents Customers
13 Market Dynamics
13.1 Neuroprotective Agents Industry Trends
13.2 Neuroprotective Agents Market Drivers
13.3 Neuroprotective Agents Market Challenges
13.4 Neuroprotective Agents Market Restraints
14 Key Findings in The Global Neuroprotective Agents Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Neuroprotective Agents Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Cerebrovascular Diseases
Table 3. Major Manufacturers of Neurodegenerative Disorders
Table 4. Major Manufacturers of Ophthalmic Diseases
Table 5. Major Manufacturers of Traumatic CNS Injuries
Table 6. Global Neuroprotective Agents Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 7. Global Neuroprotective Agents Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 8. Global Neuroprotective Agents Revenue by Region (2018-2024) & (US$ Million)
Table 9. Global Neuroprotective Agents Revenue by Region (2024-2034) & (US$ Million)
Table 10. Global Neuroprotective Agents Revenue Market Share by Region (2018-2024)
Table 11. Global Neuroprotective Agents Revenue Market Share by Region (2024-2034)
Table 12. Global Neuroprotective Agents Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 13. Global Neuroprotective Agents Sales by Region (2018-2024) & (K MT)
Table 14. Global Neuroprotective Agents Sales by Region (2024-2034) & (K MT)
Table 15. Global Neuroprotective Agents Sales Market Share by Region (2018-2024)
Table 16. Global Neuroprotective Agents Sales Market Share by Region (2024-2034)
Table 17. Global Neuroprotective Agents Sales by Manufacturers (2018-2024) & (K MT)
Table 18. Global Neuroprotective Agents Sales Share by Manufacturers (2018-2024)
Table 19. Global Neuroprotective Agents Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 20. Global Neuroprotective Agents Revenue Share by Manufacturers (2018-2024)
Table 21. Global Key Players of Neuroprotective Agents, Industry Ranking, 2021 VS 2022 VS 2024
Table 22. Neuroprotective Agents Price by Manufacturers 2018-2024 (USD/MT)
Table 23. Global Neuroprotective Agents Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 24. Global Neuroprotective Agents by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuroprotective Agents as of 2022)
Table 25. Global Key Manufacturers of Neuroprotective Agents, Manufacturing Base Distribution and Headquarters
Table 26. Global Key Manufacturers of Neuroprotective Agents, Product Offered and Application
Table 27. Global Key Manufacturers of Neuroprotective Agents, Date of Enter into This Industry
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Neuroprotective Agents Sales by Type (2018-2024) & (K MT)
Table 30. Global Neuroprotective Agents Sales by Type (2024-2034) & (K MT)
Table 31. Global Neuroprotective Agents Sales Share by Type (2018-2024)
Table 32. Global Neuroprotective Agents Sales Share by Type (2024-2034)
Table 33. Global Neuroprotective Agents Revenue by Type (2018-2024) & (US$ Million)
Table 34. Global Neuroprotective Agents Revenue by Type (2024-2034) & (US$ Million)
Table 35. Global Neuroprotective Agents Revenue Share by Type (2018-2024)
Table 36. Global Neuroprotective Agents Revenue Share by Type (2024-2034)
Table 37. Neuroprotective Agents Price by Type (2018-2024) & (USD/MT)
Table 38. Global Neuroprotective Agents Price Forecast by Type (2024-2034) & (USD/MT)
Table 39. Global Neuroprotective Agents Sales by Application (2018-2024) & (K MT)
Table 40. Global Neuroprotective Agents Sales by Application (2024-2034) & (K MT)
Table 41. Global Neuroprotective Agents Sales Share by Application (2018-2024)
Table 42. Global Neuroprotective Agents Sales Share by Application (2024-2034)
Table 43. Global Neuroprotective Agents Revenue by Application (2018-2024) & (US$ Million)
Table 44. Global Neuroprotective Agents Revenue by Application (2024-2034) & (US$ Million)
Table 45. Global Neuroprotective Agents Revenue Share by Application (2018-2024)
Table 46. Global Neuroprotective Agents Revenue Share by Application (2024-2034)
Table 47. Neuroprotective Agents Price by Application (2018-2024) & (USD/MT)
Table 48. Global Neuroprotective Agents Price Forecast by Application (2024-2034) & (USD/MT)
Table 49. US & Canada Neuroprotective Agents Sales by Type (2018-2024) & (K MT)
Table 50. US & Canada Neuroprotective Agents Sales by Type (2024-2034) & (K MT)
Table 51. US & Canada Neuroprotective Agents Revenue by Type (2018-2024) & (US$ Million)
Table 52. US & Canada Neuroprotective Agents Revenue by Type (2024-2034) & (US$ Million)
Table 53. US & Canada Neuroprotective Agents Sales by Application (2018-2024) & (K MT)
Table 54. US & Canada Neuroprotective Agents Sales by Application (2024-2034) & (K MT)
Table 55. US & Canada Neuroprotective Agents Revenue by Application (2018-2024) & (US$ Million)
Table 56. US & Canada Neuroprotective Agents Revenue by Application (2024-2034) & (US$ Million)
Table 57. US & Canada Neuroprotective Agents Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 58. US & Canada Neuroprotective Agents Revenue by Country (2018-2024) & (US$ Million)
Table 59. US & Canada Neuroprotective Agents Revenue by Country (2024-2034) & (US$ Million)
Table 60. US & Canada Neuroprotective Agents Sales by Country (2018-2024) & (K MT)
Table 61. US & Canada Neuroprotective Agents Sales by Country (2024-2034) & (K MT)
Table 62. Europe Neuroprotective Agents Sales by Type (2018-2024) & (K MT)
Table 63. Europe Neuroprotective Agents Sales by Type (2024-2034) & (K MT)
Table 64. Europe Neuroprotective Agents Revenue by Type (2018-2024) & (US$ Million)
Table 65. Europe Neuroprotective Agents Revenue by Type (2024-2034) & (US$ Million)
Table 66. Europe Neuroprotective Agents Sales by Application (2018-2024) & (K MT)
Table 67. Europe Neuroprotective Agents Sales by Application (2024-2034) & (K MT)
Table 68. Europe Neuroprotective Agents Revenue by Application (2018-2024) & (US$ Million)
Table 69. Europe Neuroprotective Agents Revenue by Application (2024-2034) & (US$ Million)
Table 70. Europe Neuroprotective Agents Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 71. Europe Neuroprotective Agents Revenue by Country (2018-2024) & (US$ Million)
Table 72. Europe Neuroprotective Agents Revenue by Country (2024-2034) & (US$ Million)
Table 73. Europe Neuroprotective Agents Sales by Country (2018-2024) & (K MT)
Table 74. Europe Neuroprotective Agents Sales by Country (2024-2034) & (K MT)
Table 75. China Neuroprotective Agents Sales by Type (2018-2024) & (K MT)
Table 76. China Neuroprotective Agents Sales by Type (2024-2034) & (K MT)
Table 77. China Neuroprotective Agents Revenue by Type (2018-2024) & (US$ Million)
Table 78. China Neuroprotective Agents Revenue by Type (2024-2034) & (US$ Million)
Table 79. China Neuroprotective Agents Sales by Application (2018-2024) & (K MT)
Table 80. China Neuroprotective Agents Sales by Application (2024-2034) & (K MT)
Table 81. China Neuroprotective Agents Revenue by Application (2018-2024) & (US$ Million)
Table 82. China Neuroprotective Agents Revenue by Application (2024-2034) & (US$ Million)
Table 83. Asia Neuroprotective Agents Sales by Type (2018-2024) & (K MT)
Table 84. Asia Neuroprotective Agents Sales by Type (2024-2034) & (K MT)
Table 85. Asia Neuroprotective Agents Revenue by Type (2018-2024) & (US$ Million)
Table 86. Asia Neuroprotective Agents Revenue by Type (2024-2034) & (US$ Million)
Table 87. Asia Neuroprotective Agents Sales by Application (2018-2024) & (K MT)
Table 88. Asia Neuroprotective Agents Sales by Application (2024-2034) & (K MT)
Table 89. Asia Neuroprotective Agents Revenue by Application (2018-2024) & (US$ Million)
Table 90. Asia Neuroprotective Agents Revenue by Application (2024-2034) & (US$ Million)
Table 91. Asia Neuroprotective Agents Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 92. Asia Neuroprotective Agents Revenue by Region (2018-2024) & (US$ Million)
Table 93. Asia Neuroprotective Agents Revenue by Region (2024-2034) & (US$ Million)
Table 94. Asia Neuroprotective Agents Sales by Region (2018-2024) & (K MT)
Table 95. Asia Neuroprotective Agents Sales by Region (2024-2034) & (K MT)
Table 96. Middle East, Africa and Latin America Neuroprotective Agents Sales by Type (2018-2024) & (K MT)
Table 97. Middle East, Africa and Latin America Neuroprotective Agents Sales by Type (2024-2034) & (K MT)
Table 98. Middle East, Africa and Latin America Neuroprotective Agents Revenue by Type (2018-2024) & (US$ Million)
Table 99. Middle East, Africa and Latin America Neuroprotective Agents Revenue by Type (2024-2034) & (US$ Million)
Table 100. Middle East, Africa and Latin America Neuroprotective Agents Sales by Application (2018-2024) & (K MT)
Table 101. Middle East, Africa and Latin America Neuroprotective Agents Sales by Application (2024-2034) & (K MT)
Table 102. Middle East, Africa and Latin America Neuroprotective Agents Revenue by Application (2018-2024) & (US$ Million)
Table 103. Middle East, Africa and Latin America Neuroprotective Agents Revenue by Application (2024-2034) & (US$ Million)
Table 104. Middle East, Africa and Latin America Neuroprotective Agents Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 105. Middle East, Africa and Latin America Neuroprotective Agents Revenue by Country (2018-2024) & (US$ Million)
Table 106. Middle East, Africa and Latin America Neuroprotective Agents Revenue by Country (2024-2034) & (US$ Million)
Table 107. Middle East, Africa and Latin America Neuroprotective Agents Sales by Country (2018-2024) & (K MT)
Table 108. Middle East, Africa and Latin America Neuroprotective Agents Sales by Country (2024-2034) & (K MT)
Table 109. Genervon Biopharmaceuticals Company Information
Table 110. Genervon Biopharmaceuticals Description and Major Businesses
Table 111. Genervon Biopharmaceuticals Neuroprotective Agents Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2018-2024)
Table 112. Genervon Biopharmaceuticals Neuroprotective Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 113. Genervon Biopharmaceuticals Recent Developments
Table 114. NeuroVive Pharmaceutical Company Information
Table 115. NeuroVive Pharmaceutical Description and Major Businesses
Table 116. NeuroVive Pharmaceutical Neuroprotective Agents Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2018-2024)
Table 117. NeuroVive Pharmaceutical Neuroprotective Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 118. NeuroVive Pharmaceutical Recent Developments
Table 119. Ceregene Company Information
Table 120. Ceregene Description and Major Businesses
Table 121. Ceregene Neuroprotective Agents Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2018-2024)
Table 122. Ceregene Neuroprotective Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 123. Ceregene Recent Developments
Table 124. Neuren Pharmaceuticals Company Information
Table 125. Neuren Pharmaceuticals Description and Major Businesses
Table 126. Neuren Pharmaceuticals Neuroprotective Agents Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2018-2024)
Table 127. Neuren Pharmaceuticals Neuroprotective Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 128. Neuren Pharmaceuticals Recent Developments
Table 129. Allon Therapeutics Company Information
Table 130. Allon Therapeutics Description and Major Businesses
Table 131. Allon Therapeutics Neuroprotective Agents Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2018-2024)
Table 132. Allon Therapeutics Neuroprotective Agents Product Model Numbers, Pictures, Descriptions and Specifications
Table 133. Allon Therapeutics Recent Developments
Table 134. Key Raw Materials Lists
Table 135. Raw Materials Key Suppliers Lists
Table 136. Neuroprotective Agents Distributors List
Table 137. Neuroprotective Agents Customers List
Table 138. Neuroprotective Agents Market Trends
Table 139. Neuroprotective Agents Market Drivers
Table 140. Neuroprotective Agents Market Challenges
Table 141. Neuroprotective Agents Market Restraints
Table 142. Research Programs/Design for This Report
Table 143. Key Data Information from Secondary Sources
Table 144. Key Data Information from Primary Sources
List of Figures
Figure 1. Neuroprotective Agents Product Picture
Figure 2. Global Neuroprotective Agents Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Neuroprotective Agents Market Share by Type in 2022 & 2034
Figure 4. Cerebrovascular Diseases Product Picture
Figure 5. Neurodegenerative Disorders Product Picture
Figure 6. Ophthalmic Diseases Product Picture
Figure 7. Traumatic CNS Injuries Product Picture
Figure 8. Global Neuroprotective Agents Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 9. Global Neuroprotective Agents Market Share by Application in 2022 & 2034
Figure 10. Hospitals
Figure 11. Clinics
Figure 12. Others
Figure 13. Neuroprotective Agents Report Years Considered
Figure 14. Global Neuroprotective Agents Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 15. Global Neuroprotective Agents Revenue 2018-2034 (US$ Million)
Figure 16. Global Neuroprotective Agents Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 17. Global Neuroprotective Agents Revenue Market Share by Region (2018-2034)
Figure 18. Global Neuroprotective Agents Sales 2018-2034 ((K MT)
Figure 19. Global Neuroprotective Agents Sales Market Share by Region (2018-2034)
Figure 20. US & Canada Neuroprotective Agents Sales YoY (2018-2034) & (K MT)
Figure 21. US & Canada Neuroprotective Agents Revenue YoY (2018-2034) & (US$ Million)
Figure 22. Europe Neuroprotective Agents Sales YoY (2018-2034) & (K MT)
Figure 23. Europe Neuroprotective Agents Revenue YoY (2018-2034) & (US$ Million)
Figure 24. China Neuroprotective Agents Sales YoY (2018-2034) & (K MT)
Figure 25. China Neuroprotective Agents Revenue YoY (2018-2034) & (US$ Million)
Figure 26. Asia (excluding China) Neuroprotective Agents Sales YoY (2018-2034) & (K MT)
Figure 27. Asia (excluding China) Neuroprotective Agents Revenue YoY (2018-2034) & (US$ Million)
Figure 28. Middle East, Africa and Latin America Neuroprotective Agents Sales YoY (2018-2034) & (K MT)
Figure 29. Middle East, Africa and Latin America Neuroprotective Agents Revenue YoY (2018-2034) & (US$ Million)
Figure 30. The Neuroprotective Agents Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 31. The Top 5 and 10 Largest Manufacturers of Neuroprotective Agents in the World: Market Share by Neuroprotective Agents Revenue in 2022
Figure 32. Global Neuroprotective Agents Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 33. Global Neuroprotective Agents Sales Market Share by Type (2018-2034)
Figure 34. Global Neuroprotective Agents Revenue Market Share by Type (2018-2034)
Figure 35. Global Neuroprotective Agents Sales Market Share by Application (2018-2034)
Figure 36. Global Neuroprotective Agents Revenue Market Share by Application (2018-2034)
Figure 37. US & Canada Neuroprotective Agents Sales Market Share by Type (2018-2034)
Figure 38. US & Canada Neuroprotective Agents Revenue Market Share by Type (2018-2034)
Figure 39. US & Canada Neuroprotective Agents Sales Market Share by Application (2018-2034)
Figure 40. US & Canada Neuroprotective Agents Revenue Market Share by Application (2018-2034)
Figure 41. US & Canada Neuroprotective Agents Revenue Share by Country (2018-2034)
Figure 42. US & Canada Neuroprotective Agents Sales Share by Country (2018-2034)
Figure 43. U.S. Neuroprotective Agents Revenue (2018-2034) & (US$ Million)
Figure 44. Canada Neuroprotective Agents Revenue (2018-2034) & (US$ Million)
Figure 45. Europe Neuroprotective Agents Sales Market Share by Type (2018-2034)
Figure 46. Europe Neuroprotective Agents Revenue Market Share by Type (2018-2034)
Figure 47. Europe Neuroprotective Agents Sales Market Share by Application (2018-2034)
Figure 48. Europe Neuroprotective Agents Revenue Market Share by Application (2018-2034)
Figure 49. Europe Neuroprotective Agents Revenue Share by Country (2018-2034)
Figure 50. Europe Neuroprotective Agents Sales Share by Country (2018-2034)
Figure 51. Germany Neuroprotective Agents Revenue (2018-2034) & (US$ Million)
Figure 52. France Neuroprotective Agents Revenue (2018-2034) & (US$ Million)
Figure 53. U.K. Neuroprotective Agents Revenue (2018-2034) & (US$ Million)
Figure 54. Italy Neuroprotective Agents Revenue (2018-2034) & (US$ Million)
Figure 55. Russia Neuroprotective Agents Revenue (2018-2034) & (US$ Million)
Figure 56. China Neuroprotective Agents Sales Market Share by Type (2018-2034)
Figure 57. China Neuroprotective Agents Revenue Market Share by Type (2018-2034)
Figure 58. China Neuroprotective Agents Sales Market Share by Application (2018-2034)
Figure 59. China Neuroprotective Agents Revenue Market Share by Application (2018-2034)
Figure 60. Asia Neuroprotective Agents Sales Market Share by Type (2018-2034)
Figure 61. Asia Neuroprotective Agents Revenue Market Share by Type (2018-2034)
Figure 62. Asia Neuroprotective Agents Sales Market Share by Application (2018-2034)
Figure 63. Asia Neuroprotective Agents Revenue Market Share by Application (2018-2034)
Figure 64. Asia Neuroprotective Agents Revenue Share by Region (2018-2034)
Figure 65. Asia Neuroprotective Agents Sales Share by Region (2018-2034)
Figure 66. Japan Neuroprotective Agents Revenue (2018-2034) & (US$ Million)
Figure 67. South Korea Neuroprotective Agents Revenue (2018-2034) & (US$ Million)
Figure 68. China Taiwan Neuroprotective Agents Revenue (2018-2034) & (US$ Million)
Figure 69. Southeast Asia Neuroprotective Agents Revenue (2018-2034) & (US$ Million)
Figure 70. India Neuroprotective Agents Revenue (2018-2034) & (US$ Million)
Figure 71. Middle East, Africa and Latin America Neuroprotective Agents Sales Market Share by Type (2018-2034)
Figure 72. Middle East, Africa and Latin America Neuroprotective Agents Revenue Market Share by Type (2018-2034)
Figure 73. Middle East, Africa and Latin America Neuroprotective Agents Sales Market Share by Application (2018-2034)
Figure 74. Middle East, Africa and Latin America Neuroprotective Agents Revenue Market Share by Application (2018-2034)
Figure 75. Middle East, Africa and Latin America Neuroprotective Agents Revenue Share by Country (2018-2034)
Figure 76. Middle East, Africa and Latin America Neuroprotective Agents Sales Share by Country (2018-2034)
Figure 77. Brazil Neuroprotective Agents Revenue (2018-2034) & (US$ Million)
Figure 78. Mexico Neuroprotective Agents Revenue (2018-2034) & (US$ Million)
Figure 79. Turkey Neuroprotective Agents Revenue (2018-2034) & (US$ Million)
Figure 80. Israel Neuroprotective Agents Revenue (2018-2034) & (US$ Million)
Figure 81. GCC Countries Neuroprotective Agents Revenue (2018-2034) & (US$ Million)
Figure 82. Neuroprotective Agents Value Chain
Figure 83. Neuroprotective Agents Production Process
Figure 84. Channels of Distribution
Figure 85. Distributors Profiles
Figure 86. Bottom-up and Top-down Approaches for This Report
Figure 87. Data Triangulation
Figure 88. Key Executives Interviewed